Status:
COMPLETED
Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients
Lead Sponsor:
Centre Hospitalier Universitaire de Nīmes
Conditions:
Trauma
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The objective of our study is to demonstrate the interest of early administration of recombinant erythropoietin in trauma patients
Detailed Description
Could an early use of rHuEPO (recombinant Human ErythroPOietin ) be lead to an individual benefice on transfusion savings after traumatic surgery?
Eligibility Criteria
Inclusion
- Patients between 18 to 65 years old
- Patient with an ASA 1 or 2 (ASA 1 corresponding to a patient in perfect health and ASA 2 to a patient with moderate involvement and well controlled organ function)
- patient presenting at least one of the following fractures: Basin and / or femur with surgical indication, associated or not with other fractures.
- patient with hemoglobin between 9 and 13 g / dl at the time of admission on trauma department
Exclusion
- patient with contraindication to synthetic erythropoietin
- Patient with intravenous iron contraindication
- pregnant patient or with a risk of pregnancy
- patient who has not given his consent or does not understand the protocol
- Patient with hemodynamic instability
- patient participating in another research protocol for less than 3 months.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03867071
Start Date
October 1 2005
End Date
July 1 2012
Last Update
March 7 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nimes university hospital
Nîmes, France, 30029